Showing results (1391-1400 of 1,448) with videos related to

Sort By:
Pageof 145
Physical Review Letters|May 30, 2020
New Measurement of ^{12}C+^{12}C Fusion Reaction at Astrophysical EnergiesW P Tan, A Boeltzig, C Dulal, et al.
Frontiers in Immunology|January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5Bin Yang, Guoqiang Fang, Isaac Marx, et al.
Biomaterials|August 22, 2018
Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip systemCarlota Oleaga, Anne Riu, Sandra Rothemund, et al.
Cancer Research|January 28, 2010
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerEvanthia Galanis, Lynn C Hartmann, William A Cliby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid TumorsAndrea E Wahner Hendrickson, Michael E Menefee, Lynn C Hartmann, et al.
Advanced Therapeutics|October 10, 2022
Classical Complement Pathway Inhibition in a "Human-On-A-Chip" Model of Autoimmune Demyelinating NeuropathiesJohn W Rumsey, Case Lorance, Max Jackson, et al.
Future Oncology (London, England)|June 19, 2023
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancerThomas J Herzog, John L Hays, Joyce N Barlin, et al.
Scientific Reports|March 17, 2017
Superconductivity in HfTe<sub>5</sub> across weak to strong topological insulator transition induced via pressuresY Liu, Y J Long, L X Zhao, et al.
Frontiers in Allergy|January 5, 2026
A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design, rationale, and methodsA J Long, S Sindher, K Martinez, et al.
Science Translational Medicine|March 29, 2019
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cellsEric L Smith, Kim Harrington, Mette Staehr, et al.
Pageof 145